High quality research reports across a broad range of industries

Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%.The aging population is growing significantly, which will increase the asthma prevalence in the Asia-Pacific region. In addition, the severity of asthma increases with age, meaning elderly patients require more medications to control their asthma symptoms, which will drive the market. In addition to the aging population, other factors such as increases in air pollution, dust, and pollen levels also contribute to the increase in asthma prevalence. Air pollution leads to both the occurrence of the disease and its exacerbation in children, and there is growing evidence of asthma symptoms in children who live near roadways in high traffic zones (Kopnina, 2012).

Biologics Growing in Prominence in Asthma Treatment

While the asthma market is dominated almost exclusively by small molecules, the pipeline is more varied. It consists of 65% small molecules, but there are also 67 biologics, equating to 24% of the pipeline.

The rise in biologic development is possibly due to the success of Xolair (omalizumab), one of the currently marketed monoclonal antibodies (mAb) in asthma therapeutics, which reached blockbuster status in 2014. Xolair is a recombinant humanized anti-IgE, and was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over with moderate-to-severe allergic asthma and symptoms not adequately controlled with inhaled corticosteroids (ICS).